Published: June 2023
The growing demand for novel drugs that can acts as potential treatments for previously untreatable intracellular targets has resulted in an adjacent and urgent need for efficient delivery systems that facilitate intracellular transport of therapeutics across the cytosol
In contemporary pharmacology, targeted therapeutics have gained significant attention, prompting the need for robust drug delivery technologies that can effectively address issues of cytotoxicity, sustained delivery, and blood-brain barrier penetration. Non-viral drug delivery systems, including cell-penetrating peptides, nanoparticles and liposomes, are being employed as viable options to overcome these challenges.
To order this 235 page report, which features 90+ figures and 120+ tables, please visit this link
Over 90 players, located across the globe, are presently offering non-viral drug delivery systems
About 55% of players engaged in this market are located in the North America, followed by those based in Europe and Asia. Further, very small and small companies represent ~70% of players in the non-viral drug delivery domain. In addition, 65% of the non-viral drug delivery systems providers are private organizations.
100 non-viral drug delivery systems are currently available in the market
Majority (71%) of the systems deliver biologics to the target site. Further, over 75% of the available systems use RNA as payload and conjugation as the most suitable type of interaction for delivering the payload intracellularly. In addition, nanoparticles emerged as the most preferred type of vehicle (45%) for delivery of payloads into the cell.
Till date, 1,140+ patents have been filed related to intracellular drug delivery technologies
The R&D activity focused on non-viral drug delivery systems is concentrated in North America and Europe. Further, nearly 55% of the total patents have been granted, followed by applications (over 40%). It is worth mentioning that most patented inventions are focused on development of nanoparticles and polymers.
Opportunity assessment framework is used to evaluate market potential of different intracellular non-viral drug delivery technologies
Our framework categorizes technologies based on market demand, using various parameters, such as patent trends, publications, grants awarded and partnership deals. Utilizing the Kalbach Innovation Model, Ansoff Matrix and BCG Matrix, it assists domain experts in making sound decisions pertaining to the market potential of non-viral drug delivery systems.
Players based in North America are anticipated to capture over 40% of the market share by 2035
In terms of type of technology, nanoparticles-based drug delivery systems (54%) are expected to capture the highest share, followed by extracellular vesicles (16%). Based on therapeutic area, ~30% of the revenue share is likely to be driven by technologies intended for the treatment of infectious diseases.
To request a sample copy / brochure of this report, please visit this link
The overall financial opportunity associated with the non-viral drug delivery systems market has been analyzed across the following segments:
The report also features inputs from eminent industry stakeholders, according to whom, the continuously growing demand for non-viral drug delivery systems is likely to drive the growth of the intracellular drug delivery market, in the foreseen future. The report includes detailed transcripts of discussions held with the following experts:
The research includes profiles of key players (listed below) engaged in this domain; each profile features a brief overview of the company, details related to its recent developments (including funding and collaborations), financial performance (if available) and an informed future outlook.
For additional details, please visit https://www.rootsanalysis.com/reports/non-viral-drug-delivery-systems-market.html or email firstname.lastname@example.org
You may also be interested in the following titles:
+1 (415) 800 3415
+44 (122) 391 1091
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry
SUBSCRIBE TO INDUSTRY UPDATES